提示: 手机请竖屏浏览!

同种异体BK病毒特异性T细胞治疗进行性多灶性白质脑病
Allogeneic BK Virus–Specific T Cells for Progressive Multifocal Leukoencephalopathy


Muharrem Muftuoglu ... 其他 • 2018.10.11

概要


JC病毒是进行性多灶性白质脑病(PML)的病因,BK病毒与JC病毒在遗传上相似,并且在免疫原性蛋白质方面具有序列同源性。我们用体外扩增、部分HLA匹配、第三方产生、冷冻保存的BK病毒特异性T细胞治疗了3例免疫抑制的PML患者。这些患者免疫抑制的原因如下:1例患者在接受脐带血移植的预处理治疗,另一例患者使用鲁索替尼治疗骨髓增殖性肿瘤,第三例患者患获得性免疫缺陷综合征。两例患者输入T细胞后,观察到PML的临床体征和影像学特征缓解,并且脑脊液(CSF)中的JC病毒被清除。另一例患者的JC病毒载量减少,症状稳定,直至第一次输入T细胞后8个月死亡。其中两例患者有免疫重建综合征。输入后在CSF中检测到供者来源的T细胞(由M. D. 安德森癌症中心[M. D. Anderson Cancer Center]奔向月球计划[Moon Shots Program]和美国国立卫生研究院资助;在ClinicalTrials.gov注册号为NCT02479698)。





作者信息

Muharrem Muftuoglu, M.D., Amanda Olson, M.D., David Marin, M.D., Sairah Ahmed, M.D., Victor Mulanovich, M.D., Sudhakar Tummala, M.D., T. Linda Chi, M.D., Alessandra Ferrajoli, M.D., Indreshpal Kaur, Ph.D., Li Li, M.D., Richard Champlin, M.D., Elizabeth J. Shpall, M.D., and Katayoun Rezvani, M.D., Ph.D.
From the Departments of Stem Cell Transplantation and Cellular Therapy (M.M., A.O., D.M., S.A., I.K., L.L., R.C., E.J.S., K.R.), Infectious Diseases (V.M.), Neuro-Oncology (S.T.), Diagnostic Radiology (T.L.C.), and Leukemia (A.F.), M.D. Anderson Cancer Center, Houston. Address reprint requests to Dr. Rezvani at the Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 448, Houston, TX 77030-4009, or at krezvani@mdanderson.org.

 

参考文献

1. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971;1:1257-1260.

2. Zurhein G, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science 1965;148:1477-1479.

3. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425-437.

4. Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant 2007;39:101-107.

5. Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 2017;88:1197-1205.

6. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009;60:3761-3765.

7. Ferenczy MW, Marshall LJ, Nelson CD, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012;25:471-506.

8. Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 2015;8:255-273.

9. Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, Tognon M. BK virus, JC virus and Simian Virus 40 infection in humans, and association with human tumors. Adv Exp Med Biol 2006;577:319-341.

10. Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2017;35:3547-3557.

11. Krymskaya L, Sharma MC, Martinez J, et al. Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol 2005;79:11170-11178.

12. Cantalupo P, Doering A, Sullivan CS, et al. Complete nucleotide sequence of polyomavirus SA12. J Virol 2005;79:13094-13104.

13. Li J, Melenhorst J, Hensel N, et al. T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J Gen Virol 2006;87:2951-2960.

14. Koralnik IJ, Du Pasquier RA, Kuroda MJ, et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 2002;168:499-504.

15. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013;80:1430-1438.

16. Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007;196:709-711.

17. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013;121:5113-5123.

18. Balduzzi A, Lucchini G, Hirsch HH, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 2011;46:987-992.

19. Alstadhaug KB, Croughs T, Henriksen S, et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol 2014;71:1030-1035.

20. Kunschner L, Scott TF. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 2005;65:1510-1510.

21. Sospedra M, Schippling S, Yousef S, et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 2014;59:1588-1592.

服务条款 | 隐私政策 | 联系我们